Hydrinity RetaXome Daily Retinal Hydrator 30ml

Hydrinity RetaXome Daily Retinal Hydrator is a next-generation retinal treatment engineered to deliver the regenerative benefits of a potent retinoid while minimising the irritation typically associated with this ingredient class. Retinal is encapsulated within a proprietary, precision-targeted biomimetic exosome, preserving its potency and enabling deeper, more controlled dermal delivery.

Benefits

• Supports epidermal cell turnover and collagen and elastin synthesis
• Improves the appearance of fine lines, wrinkles and photodamage*
• Reduces visible redness and inflammation*
• Enhances skin texture and firmness*
• Delivers deep, sustained hydration via a hyaluronic acid–retinoid hybrid molecule

Good For

Formulated for all skin types, including sensitive skin and individuals unable to tolerate traditional retinoids. Clinical data indicates that patients previously intolerant to conventional retinoid formulations were able to incorporate RetaXome into their routine without irritation*.

Key Ingredients

• Retinal — encapsulated in RetaXome™ Technology; penetrates the dermis to support cell turnover and stimulate collagen and elastin production.
• Centella Asiatica — a medicinal plant extract that helps calm irritation, reduce inflammation and support the skin's natural repair process.
• Sodium Retinoyl Hyaluronate — a hybrid molecule combining the resurfacing action of a retinoid with the hydrating properties of hyaluronic acid.
• Adaptogen Mushroom Complex — an antioxidant-rich blend of adaptogenic fungi that defends against environmental stressors while calming stressed skin.
• Ectoin — a naturally derived molecule that reinforces the skin barrier, enhances hydration and helps protect against UV and blue light damage.

Directions

• Cleanse skin thoroughly before application.
• Apply a small amount to face and neck once daily in the evening.
• Can be used nightly from the first application, with no acclimation period required.

Clinical Results

Efficacy was assessed in a 12-week, single-centre, IRB-approved, open-label study involving 20 female patients (ages 35–65; Fitzpatrick I–VI) presenting with mild to moderate fine lines, wrinkles and photodamage.

• 100% of patients previously unable to tolerate retinoids were able to use RetaXome*
• 68% reduction in the appearance of redness and inflammation**
• 62% improvement in skin texture**

Size: 30ml

Individual results may vary.
*Based on 2-week patient-observed results.
**Based on 12-week patient-observed results.